FDA commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this ...

The strongest evidence for use of the drugs so far came from trials in patients with severe depression or post-traumatic ...

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use ...

President Trump signed an executive order to fast-track the study of using psychedelic drugs to treat Americans – especially ...

The agency issued "national priority vouchers" for the two drugs six days after President Donald Trump promised to facilitate ...

The agency issued priority vouchers for 3 experimental new drugs using psilocybin and methylone, amid Trump’s ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to ...

The FDA has introduced a new priority review voucher program for three psychedelic drug candidates, including psilocybin for depression, following President Trump's executive order to accelerate ...

A new study compared psilocybin with a common SSRI and found that both drugs improved symptoms, while psilocybin provided added benefits. Maki Nakamura/Getty Images Psilocybin is the active ingredient ...

In a comparison of depression treatment trials, control group outcomes in trials of psilocybin were lower than those in trials of SSRIs and esketamine. This may suggest that psilocybin's ...

Depression is a debilitating mental health disorder that is estimated to affect approximately 5% of people worldwide. It is ...